Compare Citius Pharmaceuticals Inc (CTXR) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ecolab Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Ecolab Inc. trades at $281.36 (market cap $77.96B). The key difference: Ecolab Inc. is far larger — about 5653.4× Citius Pharmaceuticals Inc's market cap, and Ecolab Inc. pays a 1.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Ecolab Inc. for 90 Days on average.
| CTXR | ECL | |
|---|---|---|
Market Cap | $13.79M | $77.96B |
Volume | 156,684 | 1,145,536 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $308.35 |
52-Week Low | $0.48 | $245.73 |
Typical Hold Time | 16 Days | 90 Days |
Enterprise Value | $3.96M | $86.74B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Ecolab (ECL) trades at $281.69, up 0.31% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $326.38. The company reported revenue of $16.08B in 2025 with a net income margin of 12.57%, and recent earnings have mostly met or exceeded expectations. Strong institutional buying and insider purchases, alongside positive news coverage highlighting its dividend growth and essential business model, support a constructive outlook.
The stock presents a favorable risk-reward profile given its steady revenue growth, high profitability, and analyst optimism, though elevated valuation ratios and increased debt from the CoolIT acquisition pose risks. The upcoming Q3 2026 earnings report on October 27, 2026, will be a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
